Ultromics, the Oxford-based artificial intelligence diagnostics company, has completed a $55 million Series C funding round to expand its AI-powered heart failure detection platform across U.S. hospitals. The investment positions the company to address diagnostic gaps in cardiovascular care that affect millions of patients annually.
The funding round attracted co-leadership from L&G, Allegis Capital, and Lightrock, alongside continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Notable participation came from two major U.S. health systems: University of Chicago Medicine and UPMC Enterprises.
Targeting Diagnostic Blind Spots in Cardiology
Ultromics has developed the first FDA-cleared, Medicare-reimbursed AI technology specifically designed to detect Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis. These conditions represent some of the most challenging diagnoses in cardiology, with up to 64 percent of HFpEF cases going undiagnosed according to the company’s data.
The company’s EchoGo platform analyzes standard echocardiograms using artificial intelligence to identify disease signals that traditional interpretation methods often miss. Built on analysis of hundreds of thousands of echocardiograms, the system provides real-time probability scores to help cardiologists identify high-risk patients earlier than conventional approaches.
“The reality is, hospitals already have the data, they just haven’t had the tools to extract diagnostic signals from it” said Ross Upton, CEO and Founder of Ultromics.
Clinical Validation and Market Performance
Clinical studies demonstrate that EchoGo improved HFpEF detection by 73.6 percent compared to standard risk scores. The platform has analyzed over 430,000 echocardiograms to date, with validation occurring through global studies across 18 institutions for its cardiac amyloidosis diagnostic model.
The technology integrates into existing clinical workflows without requiring new hardware, addressing a key adoption barrier in hospital settings. Medicare reimbursement coverage for both outpatient and inpatient use supports broader implementation across healthcare systems.
Strategic Partnerships and Market Expansion
Ultromics has established partnerships with flagship medical institutions including University of Chicago Medicine, University Hospitals Cleveland, Northwestern University, and Mayo Clinic. The company reports building regional clusters of clinical and commercial traction, particularly in the Midwest where heart failure prevalence runs high.
“Ultromics has established itself as an early mover in the large and underserved cardiovascular disease market” ~ Alastair Stewart, Head of Investments at L&G.
Recent regulatory milestones include FDA Breakthrough Device clearance for EchoGo Amyloidosis in late 2024, followed by the 2025 launch of EchoGo Score for enhanced HFpEF detection capabilities.
Investment Focus and Growth Strategy
The Series C proceeds will fund U.S. market expansion and international growth in priority markets, with emphasis on hospitals and echo labs serving high volumes of at-risk patients. Ultromics plans to establish AI-powered diagnostics as standard practice in cardiac assessments.
“What’s exciting about Ultromics is how they’re closing that gap” ~ Victor Westerlind, Managing Director at Allegis Capital.
The company intends to broaden its product pipeline to cover additional cardiac conditions while strengthening distribution channels and clinical collaborations. This expansion strategy targets the estimated millions of patients with treatable heart failure who currently receive delayed or missed diagnoses due to subtle symptoms and complex echocardiogram interpretation requirements.
Lightrock’s Umur Hursever emphasized the technology’s real-world impact, stating that the platform improves diagnostic accuracy while supporting clinical decisions and expanding access to specialist care. The investment reflects growing recognition of AI’s role in addressing healthcare system burdens created by cardiovascular disease.